Table 4.

Fc Portion Alignment of Currently Published X-Ray Structures

Fc Portion 1	Chain	Residues	Fc Portion 2	PDB Entry	Chain	Residues	RMSD/Åa
Anti-NPRA	H	237–443	Pembrolizumab	5DK3	B	219–443	9.573	NPRA versus 5DK3 (isolated Fc portions)
Anti-NPRA	H	237–443	Pembrolizumab		G	219–443	0.939
Anti-NPRA	K	237–443	Pembrolizumab		B	219–443	9.166
Anti-NPRA	K	237–443	Pembrolizumab		G	219–443	0.799
Anti-NPRA	H	237–443	rhu IgG4-Fc	4C54	A	236–443	0.851	NPRA versus 4C54
Anti-NPRA	H	237–443	rhu IgG4-Fc		B	236–443	0.851
Anti-NPRA	K	237–443	rhu IgG4-Fc		A	236–443	0.509
Anti-NPRA	K	237–443	rhu IgG4-Fc		B	236–443	0.719
Anti-NPRA	H+K	237–443	rhu IgG4-Fc		A+B	236–443	0.829
Anti-NPRA	H	237–443	sdhu IgG4-Fc	4C55	A	237–443	0.988	NPRA versus 4C55
Anti-NPRA	H	237–443	sdhu IgG4-Fc		B	237–443	0.515
Anti-NPRA	K	237–443	sdhu IgG4-Fc		A	237–443	0.668
Anti-NPRA	K	237–443	sdhu IgG4-Fc		B	237–443	0.644
Anti-NPRA	H+K	237–443	sdhu IgG4-Fc		A+B	237–443	0.754

^aValues are generated by superimposition of individual Fc portions as outlined using PyMOL (29).